Dual-specificity phosphatases (DUSPs) is an emerging subclass of the protein tyrosine phosphatase gene superfamily, a heterogeneous group of protein phosphatases that can dephosphorylate both phosphotyrosine and phosphoserine/ phosphothreonine residues within the one substrate. Recently, a series of investigations of DUSPs defined their essential roles in cell proliferation, cancer and the immune response. This review will focus on DUSP2, its involvement in different diseases and its potential as a therapeutic target.
INTRODUCTION
Mitogen-activated protein kinase (MAPK) activation cascades mediate various physiological processes, such as cell proliferation, differentiation, stress responses, inflammation, apoptosis and immune defense. [1] [2] [3] [4] Dysregulation of MAPK activation cascades has been implicated in various diseases and has been the focus of extensive research. [5] [6] [7] MAPKs are grouped into three major classes based on their preferential activation by extracellular stimuli: classic Erk1 and Erk2 and p38 proteins (p38a, p38b, p38g and p38 d) and Jun N-terminal kinases (Jnk1, Jnk2 and Jnk3). These are all activated by dual phosphorylation of the threonine and tyrosine residues in a conserved 'TXY' (Thr-Xaa-Tyr) motif (where X is E for Erk, G for p38 or P for Jnk).
Dual-specificity phosphatases (DUSPs) are an emerging subclass of the protein tyrosine phosphatase gene superfamily, a heterogeneous group of protein phosphatases that can dephosphorylate both phosphotyrosine and phosphoserine/ phosphothreonine residues within the one substrate. 8 They can regulate activity of MAPK through TXY motif dephosphorylation as well as represent particularly important negative regulators. 8, 9 In addition to their dephosphorylating capacity, DUSPs serve to anchor or shuttle MAPKs and control their subcellular localization. 10, 11 The human genome contains 30 putative DUSP genes, 11 of which are specific for the MAPKs Erk, Jnk and p38. 12, 13 Those genes have been referred to as MAP kinase phosphatases (MKPs). 13 Another subgroup of DUSPs contains 19 DUSPs, which have been referred to as 'atypical' DUSPs. 13 Some of them have been shown to regulate MAPKs as they share some characteristic of the MKPs. They contain the DUSP catalytic domain but lack the N-terminal CH2 domain found in MKPs. 14 Different members of the family of MKPs show distinct substrate, different tissue distribution and subcellular localization, and different modes of inducibility of their expression by extracellular stimuli. Inducible nucleuses MKPs include DUSP1, DUSP2, DUSP4 and DUSP5, which originated from a common ancestral gene. They were shown to dephosphorylate Erks, Jnk and p38 MAPKs to the same extent and to be induced by growth or stress signals. DUSP6, DUSP7 and DUSP9 are cytoplasmic Erkspecific MPKs, which can preferentially recognize Erk1 and Erk2 in vitro. DUSP8, DUSP16 and DUSP10 are cytoplasmic and nuclear. They recognize Jnk and p38 and can inactivate p38 and Jnk MAPKs. 15, 16 They negatively regulate members of the MAPK superfamily (MAPK/Erk, SAPK/Jnk and p38), which are associated with cellular proliferation and differentiation. As major regulators of MAPK signaling, DUSPs have been implicated as major modulators of the critical signaling pathways that are dysregulated in various diseases.
Recently, a series of investigation in DUSPs defined essential roles in cell proliferation and cancer [17] [18] [19] [20] [21] [22] [23] and their immune response. 4, 24 Although there are at least 11 MKPs (many of them were thought to have a similar role to regulate MAPK cascades), it is obvious that each of them has different substrate specificities and physiological roles. This review will focus on one of the DUSPs: DUSP2. We will present what is currently known about its involvement in different diseases and potential as a therapeutic target.
HISTORY AND BASIC FUNCTIONS OF DUSP2
DUSP2 has also been referred to as the phosphatase of activated cells 1. It is a 32-kDa protein, originally cloned in 1993 from human T cells as an immediate-early gene.
25 DUSP2 localizes in the nucleus and is predominantly expressed in hematopoietic tissues with high T-cell content, such as thymus, spleen, lymph nodes, peripheral blood and other organs (brain and liver). [25] [26] [27] [28] Its expression is induced rapidly in mitogen-stimulated T and B cells after stimulation. 25, 29 As a member of the dual-specificity protein phosphatase subfamily, DUSP2 inactivates its target kinases by dephosphorylating both the phosphoserine/threonine and phosphotyrosine residues. 8 It is a member of MKPs with protein tyrosine phosphatase and CH2 domains. 13, 30 Similar to the other members of DUSP family, the function of DUSP2 has been described as a typically negative regulator of MAPK signaling. DUSP2 can preferentially dephosphorylate Erk1/2 and p38 but not Jnk in vitro. 31, 32 Although there have been reports of low phosphatase activity of DUSP2 for Jnk in vitro, 31 DUSP2 deficiency has led to increased activity of Jnk and unexpected impairment of the activity of extracellular Erk and p38. 4 The DUSP2 signaling pathways are shown in Figure 1 .
Erk1/2 is phosphorylated on Tyr and Thr residues and activated by growth factors such as platelet-derived growth factor, 33, 34 epidermal growth factor, 33 nerve growth factor, 35 and in response to insulin. 36, 37 Activation of Erk1/2 has a central role in many cellular responses, such as cell motility, proliferation, differentiation and survival. 38, 39 Activation of the Erk pathway can protect pancreatic tumor cells from apoptosis and regulate their progression in the cell cycle. 40 As the convergence point of most mitogenic signaling pathways, Erk is becoming an ideal target for treatment of human cancer. In addition, the Erk subfamilies of MAPKs are essential in innate immunity. 41, 42 Notably, Erk2 is a physiological substrate for DUSP2, and it forms a tight complex with DUSP2 43 that includes the amino-terminal domain. 44 DUSP2 has two conserved, positively charged amino-acid residues (Arg294 and Arg295), which are important for binding to the phosphothreonine of Erk2. 44 Mutation of either residue alone or in combination lead to a nearly complete loss of Erk2-induced catalytic activation of DUSP2 and its ability to dephosphorylate Erk2.
43 DUSP2 contributes to the dephosphorylation of protein kinase C-activated Erk2 in the nucleus, inactivating and anchoring it. DUSP2, together with DUSP1 and DUSP4, regulates Erk2 dephosphorylation and compartmentalization in response to sustained protein kinase C-mediated signaling. Overexpression of DUSP2 prevents Erk2 activation and causes Erk2 nuclear accumulation or immunoprecipitation with Erk2. 45 Similarly, p38 MAPK is phosphorylated on Tyr and Thr residues and, generally, is more responsive to stress stimuli. 46 The p38 can be strongly activated by various environmental stresses, such as oxidative stress, ultraviolet irradiation, hypoxia and ischemia. 47 P38 MAPKs have also been shown to have roles in cell proliferation and survival. The a-subtype of p38 can negatively regulate cell-cycle progression and apoptosis. 48, 49 P38 also has an important role in normal immune and inflammatory responses 47 and is activated in macrophages, neutrophils and T cells by numerous extracellular mediators of inflammation (including chemoattractants, cytokines, chemokines and bacterial lipopolysaccharide). 50 It is critical for activation of some transcriptions that control the expression of proinflammatory cytokine genes (including interleukin-1, NF-kB and tumor necrosis factor-a. [51] [52] [53] [54] Deletion of the p38 in epithelial cells can reduce proinflammatory gene expression. 55 It has been shown that transfection of DUSP2 in NIH 3T3 and HeLa cells inhibits p38a-mediated phosphorylation of its substrate, ATF2, 31 suggesting that DUSP2 can dephosphorylate p38a effectively in vivo. In contrast, in vitro results demonstrated that DUSP2 can form a stable complex with p38a. However, this direct binding does not result in dephosphorylation of p38a by DUSP2, nor cause any catalytic activation of DUSP2. 43 This result is similar to another nuclearspecific MPK (MKP-2/DUSP4). 56 Zhang et al 43 speculated that the reason for the contrasting results could be because of another protein that co-associates with them in vivo.
Alternatively, Jnk2 is not considered to be a physiological substrate for DUSP2 because it neither stimulates the catalytic activity of the phosphatases nor is dephophorylated by DUSP2. 43 Another report showed that DUSP2 cannot inhibit the ability of Jnk2 to phosphorylate the kinase's substrate c-Jun in vivo. 31 However, Jeffrey et al. 4 demonstrated that Jnk activity was increased in DUSP2-deficient macrophages and mast cells. Moreover, SP600125, a specific inhibitor of Jnk, could completely restore the decline of Erk activity in DUSP2-deficient mast cells. DUSP2 may acts as a negative regulator of Jnk, therefore resulting in negative cross-talk between Jnk and Erk. 4 There is still a lack of direct evidence of DUSP2's effect on Jnk. Further research is also needed to confirm the complex of roles of DUSP2 on Jnk MAPK.
Although overexpression of DUSP2 appears to dephosphorylate Erk and p38, 31 deletion of DUSP2 unexpectedly impaired the activity of Erk and p38 in macrophages and mast cells and increased Jnk activity. 4 It should be noted that the decreased Erk activity could be restored completely with a specific inhibitor of Jnk, suggesting that DUSP2 can increase activation of Erk by blocking Jnk. A negative cross-talk relationship between the stress-activated JNK pathway and the mitogen-activated ERK pathway has been previously described. 57 The authors considered that sustained Jnk activation uncouples Erk activation from MEK in a manner that requires Jun-mediated gene transcription. Junttila et al. 58 stated that Jnk/p38-mediated mechanisms negatively regulate the Erk pathway; therefore, the function of the Erk pathway was considered as survival promoting, contrasting with the proapoptotic activity of the stress-activated c-Jun Jnk/p38 MAPK pathways. These results are consistent with the results of Jeffrey et al. 4 Moreover, it was postulated that DUSP2 interacts with p38, Jnk and Erk, providing a basis for the cross-talk between MAPK. 59 The importance of DUSP2 as a regulator of Erk, p38 and Jnk-dependent biological processes and specific functions is discussed below in detail.
ROLE OF DUSP2 IN IMMUNE REGULATION AND INFECTIOUS DISEASE
There are three major MAPK family members (p38, Erk and Jnk) expressed in the immune system 60 (Table 1) . They are activated by environmental stresses, and their main role is as inflammatory mediators. 61 They are all activated downstream of innate immunity's TLR to induce the production of cytokines and inflammatory mediators. The early and robust DUSP2 transcription in immune cells suggests that it is an important regulator of nuclear MAPK events after receptor activation. Expression of DUSP2, which is different from the other members of its family, is limited to the immune cells, highlighting its importance to immune-mediated inflammatory reactions. In addition, it also identifies DUSP2 to be highly induced in T and B cells after activation. 25, 29 Furthermore, it indicates the important and unique features of DUSP2, which is to regulate immune cell effector functions via MAPK signaling.
DUSP2-KNOCKOUT MODEL EXHIBITS IMMUNE AND INFLAMMATORY RESPONSES
It is known that dephosphorylated MAPKs have a negative regulatory role in MAPK signaling and cellular responses, similar to other members of the DUSPs. As in DUSP1 À / À and DUSP10 À / À mice, the immune system of DUSP2 À / À mice developed normally. 62 However, contrary to the negative effects of other DUSP deficiency (such as DUSP1 and DUSP10), DUSP2 has an unexpected positive function in the induction and perpetuation of certain inflammatory responses in an autoimmune model of rheumatoid arthritis.
62 DUSP2 is the most highly induced DUSP transcript in activated human leukocytes, and DUSP2 proteins associate with human inflammatory tissue (rheumatoid arthritis synovium and tonsil). 62 In addition, Dusp2 À / À mice showed greatly diminished clinical and histological features of arthritis. DUSP2-deficient mast cells and macrophages produce fewer inflammatory mediators, such as tumor necrosis factor and IL-6, after being stimulated by TLR and FceR. The numbers of IL-12-producing cells and the amount of IL-12 per cell were reduced; also, there was a considerably reduced production of prostaglandin E2 and nitric oxide after stimulation of DUSP2-deficient macrophages. Phosphorylation of Erk and p38 decreased in DUSP2-deficient macrophages and mast cells. The gene deletion also reduced transcriptional Elk1 and NFAT-AP-1 activity, which are effectors downstream of MAPKs. Because of an increased rate of apoptosis, DUSP2-deficient mast cells exhibited decreased survival. In spite of the fact that there is no direct evidence showing that DUSP2 has an obvious function in immune cell development, overexpression of DUSP2 in cells enhanced inflammatory mediator production. 4 In aggregate, these findings suggest that DUSP2 has a critical and positive role in inflammatory responses.
DUSP2 OUTSIDE THE IMMUNE SYSTEM
The MAPK signal pathway has an important role in not only the process of cell growth, proliferation and differentiation but also in cell-growth suppression and apoptosis, which is often dysregulated in cancers. The upstream components of the MEK/Erk pathway are associated with the oncogenic process. P38 and Jnk may also have a role as tumor suppressors in some conditions. 15, 63 The dual-specificity MKPs are also essential for the initiation and development of cancer. As one of the inducible nuclear MKPs, nuclear-specific DUSP2 is controlled by immediately early genes that are induced by activated MAPKs upon nuclear entrance. The oxidative stress-dependent high level of DUSP2 induction promotes apoptotic cell death.
25
DUSP2 in human cancers-a potential biomarker of diseases DUSP2 was originally cloned from hematopoietic cells; therefore, studies of DUSP2 initially focused on the role in the immune system. In recent years, the role of DUSP2 in pathological processes of human cancers has been of great interest to researchers. Initially, DUSP2 was described as a maximally expressed protein tyrosine phosphatase in the hematopoietic tissue, which had a distinct role in the inactivation of the Erk signaling pathway. Studies indicated that activation of the Erk cascade increases the expression of DUSP2. 25, 32 However, the expression of DUSP2 is unexpectedly downregulated in human acute leukemias, and this downregulation of DUSP2 significantly correlated with hyperexpression of Erk activation. 17 Recently, Lin et al. 18 reported that DUSP2 mRNA and protein are significantly reduced in most solid cancers (such as cancerous breast, colon, lung, ovary, kidney and prostate), and suppression of DUSP2 is associated with tumorigenesis and malignancy ( Table 1) . Expression of DUSP2 is downregulated in cancer cells after inhibition by HIF-1a, whereas the expression of other nuclear Dual-specificity phosphatases 2 effect in diseases W Wei et al DUSPs (DUSP1, -4 and -5) is upregulated under the same conditions. 18 This suggests that DUSP2 is a key nuclear DUSPs for negative regulation of Erk phosphorylation in hypoxic cells. In addition, it is demonstrated that hypoxia-inhibited DUSP2 expression is primarily controlled by HIF-1a in multiple cancer cell types, thus enabling prolonged Erk phosphorylation. DUSP2 induces apoptosis, inhibits tumor growth and abolishes hypoxiainduced drug resistance. 18 However, inhibition of DUSP2 expression can increase drug resistance. 18 There are five genes that are negatively regulated by DUSP2. Those genes are early growth response protein 1, multidrug resistance, cysteine-rich angiogenic inducer 61, glucose-regulated protein 78 and osteopontin, which exert distinct functions via different signaling pathways, causing drug resistance. Sano et al. 19 attempted to identify potent marker genes of breast cancer through a prediction model for individual response to epirubicin/ cyclophosphamide combination chemotherapy (EC). Ultimately, they selected DUSP2 as one of the reliable prediction markers. As a transcriptional target of p53, DUSP2 is induced in response to both ZnCl2 and serum deprivation, which activates p53 and induces apoptosis in a human colon cancer cell line (EB-1 cells).
20
DUSP2 mRNA was reported to be downregulated in most cancers, but it was upregulated in cells of effusions from ovarian serous carcinoma. 21 Givant-Horwitz et al. 21 detected mRNA expression of the DUSP1, -2, -9 and -10 in 39 malignant effusions from patients diagnosed with serous ovarian carcinoma. The results showed that DUSP1 and -2 are expressed in the vast majority of cells; however, DUSP9 and DUSP910 were uniformly absent. Furthermore, DUSP1 showed no association with clinicopathological parameters, but high DUSP2 expression was significantly correlated with poor prognosis. This also suggests that DUSP2 is a true negative regulator of MAPK in ovarian carcinoma cells present in effusions. Abbreviations: DUSP, dual-specificity phosphatase; NO, nitric oxide; PGE2, prostaglandin E2; TNF, tumor necrosis factor. See text for more details.
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The functions of DUSP2 in cancer cell apoptosis There are two MAP kinase inhibitors, DUSP2 and DUSP4 (MKP-2), that are considered to be downstream targets of p53 function in apoptosis signaling. 20, 22 DUSP2 is a transcriptional target of p53 in signaling apoptosis and tumor suppression in vivo. It is the first reported p53 downstream gene that is required for p53-mediated apoptosis in response to oxidative stress. P53 activates transcription of DUSP2 via binding to a palindromic site in DUSP2 promoter during apoptosis. DUSP2 has been shown to be transcriptionally induced by the human tumor-suppressor protein p53 in the cell's response to serum deprivation and oxidative stress. Moreover, DUSP2 acts as a key downstream effector of p53 function to suppress the MAPK cascade and to induce cell-growth suppression and apoptosis. 20 DUSP2 has also been found to be a direct transcriptional target of E2F-1 in apoptotic signaling 23 (Table 1) . E2F-1 is expressed in cancer cells. E2F-1 mediates the activity of the RB tumor suppressor and has a crucial role in the control of the cell cycle through transcriptional regulation of its target genes. In breast cancer cells, expression of DUSP2 can be increased by ectopic E2F-1 at both transcriptional and translational levels. Furthermore, E2F-1 suppresses Erk activity through DUSP2 to enhance the sensitivity of cancer cells to chemotherapeutic agent N-4-hydroxyphenylretinamide treatment, which leads to elimination of cancer cells by apoptosis. As described above, these findings reveal a mechanistic link between hypoxia and ERK activation, the two critical factors in cancer progression and malignancy. The specific mechanism of DUSP2 in vivo remains obscure. As a dual target in the two fundamental pathways and a merger site for apoptosis, DUSP2/ MAPK cascades in cancer cell death provide a molecular basis in cancer therapy for the future. Furthermore, as a potential biomarker of diseases, DUSP2 has broad prospects in cancer diagnosis.
DUSP2 in other diseases
It is notable that recent research showed that hypoxia-inhibited DUSP2 expression is a critical factor for the development of endometriosis 64 ( Table 1) . Expression of DUSP2 is downregulated in endometriotic stromal cells and is transcriptionally suppressed by HIF-1a. 64 Furthermore, hypoxia, via downregulation of DUSP2, induces ERK and p38 MAPK phosphorylation and cyclooxygenase-2 overexpression. 64 In rats, seizures can induce DUSP2 expression in microglial cells, and DUSP2 may have an important role in controlling MAP kinase involvement in both neuronal death and neuroinflammation after excitotoxic damage. 27 DUSP2 expression was increased in lymphocytes of all neuronal ceroid lipofuscinosis (CLN) patients with or without medication, as well as in murine neuronal cells harboring the patient's genetic CLN3 defect and in acutely CLN3-depleted nonneuronal and neuronal cells. Therefore, DUSP2 is considered to be a potential biomarker of CLN3 disease. 65 
GENOMIC ASPECT OF DUSP2
Based on information from Ensembl (http://www.ensembl.org/ index.html), DUSP2 is located in humans on chromosome 2 between 96808905 and 96811179 bp (GRCh37). It encodes two transcripts, but only one produces a protein of 314 amino acid. In mice, it is also located on chromosome 2, but between 127161895 and 127164112 bp. The gene also encodes two transcripts; one of them produces a protein of 318 amino acid. The mouse and human protein have an 88% identity, thus are substantially different. According to the single-nucleotide polymorphism database (http://www.ncbi.nlm.nih.gov/snp), there are 75 known single-nucleotide polymorphism in human populations, whereas there are only 18 known single-nucleotide polymorphism in mice that map to this region. The fact that there is only one protein product of the DUSP2 gene and no alternative splice variants suggest that it may be a suitable therapeutic target. The multiple functions of this single protein may be because of: 1) expression level-related functions; 2) tissue-specific expressions for different functions; and 3) polymorphism of genes for variations of phenotypes in human populations. To utilize DUSP2 in therapeutic applications, it will be essential to understand the regulation of expression at transcriptional and translational levels, as well as the potential impact of polymorphisms of DUSP2.
CONCLUSION
The critical role exerted by DUSP2 has been shown by its multiple levels of regulation and its regulation in multiple diseases. Understanding the physiological roles of DUSP2 may pave the way for developing new therapies for immune diseases, inflammation, cancer or other diseases, and further understanding of MAPK signaling in physiological responses.
